By investing across public and private markets, Foresite creates a positive feedback loop. Understanding what public investors value (e.g., product-centric assets for unmet needs like pancreatic cancer) directly influences the firm's strategy for incubating and building new companies from scratch.

UCB's acquisition of Candid (BCMA, CD20) following a licensing deal for a CD19 engager reveals a larger pharma trend. Companies are building pipelines covering the main B-cell targets to hedge their bets before a single target proves dominant for specific autoimmune diseases.

Eli Lilly’s acquisition of in-vivo CAR-T company Colonia Therapeutics signals a deliberate strategy to bypass the crowded and still unproven allogeneic cell therapy space. By investing directly in technology that modifies T-cells inside the body, Lilly is betting it can leapfrog the current generation of cell therapies toward a more scalable platform.

While scientifically novel, the primary advantage of in vivo CAR-T therapy is its potential to overcome the significant logistical barriers of traditional CAR-T. By simplifying the process to a single injection, it could democratize access for patients far from specialized academic medical centers.

Despite initial hype in oncology where business models struggled, cell therapy is finding a major new application in treating autoimmune diseases. By resetting the immune system, it can offer functional cures for debilitating conditions—a powerful and unexpected pivot for the technology platform.

While some firms repurpose cancer T-cell engagers (TCEs), a new wave of innovation is emerging from China. These biotechs are designing novel, "fit-for-purpose" constructs like trispecifics and molecules with co-stimulatory receptors specifically for the unique safety and efficacy demands of autoimmune disease.

In the competitive autoimmune T-cell engager (TCE) field, UCB's acquisition of Candid highlights a key M&A driver: having even early Phase 1 clinical proof-of-concept significantly de-risks an asset and commands a premium valuation over preclinical competitors.

The commercial challenges of Bluebird Bio's "single therapy for a single patient" model were a key catalyst for the industry's evolution. This reality pushed the field toward developing more economically viable and broadly applicable technologies, like in vivo CAR-T, that can reach more patients globally.

Major players are repurposing oncology's T-cell engager technology for autoimmune diseases. Gilead's $1.675B acquisition of Oral Medicines and Sanofi's $1.05B potential deal with Kali Therapeutics highlight a strategic shift to leverage this powerful modality in a new, high-potential therapeutic area.